VERIANOS SE

  • WKN: A0Z2Y4
  • ISIN: DE000A0Z2Y48
  • Land: Deutschland

Nachricht vom 24.11.2021 | 16:10

VERIANOS SE decides to increase share capital without subscription rights

VERIANOS SE / Key word(s): Capital Increase/Corporate Action
VERIANOS SE decides to increase share capital without subscription rights

24-Nov-2021 / 16:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


VERIANOS SE decides to increase share capital without subscription rights

Cologne/Frankfurt am Main, 24.11.2020 - The Board of Directors of VERIANOS SE today resolved to increase the company's share capital - excluding subscription rights. As a result, 1,250,000 new registered no par value shares are to be issued against cash contributions.

The target group of the capital increase are further strategic investors associated with the company. The proceeds will be used to finance further growth. The new shares will be issued by way of a capital increase from the authorized capital approved by the Annual General Meeting on 19 July 2018. As a result of the capital increase, the company's share capital will rise from EUR 12,500,000 to EUR 13,750,000.

 

This publication constitutes neither an offer to sell nor a solicitation to buy any securities.

Contact:
VERIANOS SE
Investor Relations - Tobias Bodamer
T +49 69 69 768 88 100
Email: ir@verianos.com


Financial and business press
IR.on AG
Frederic Hilke
T +49 221 9140 970
Email: verianos@ir-on.com


24-Nov-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021